{"id":20239,"date":"2014-04-24T11:17:29","date_gmt":"2014-04-24T15:17:29","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=20239"},"modified":"2014-04-24T11:17:29","modified_gmt":"2014-04-24T15:17:29","slug":"amgen-inc-nasdaqamgn-decline-in-enbrel-sales","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239","title":{"rendered":"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 04\/24\/2014 (wallstreetpr) &#8211;\u00a0<strong>Amgen, Inc. (NASDAQ:AMGN)<\/strong> failed to meet the market expectations on its earnings in the first quarter 2014. The revenues didn\u2019t come in line with as per market expectations. The main reason for the fall in revenues is the lower Enbrel Sales. The company raises prices of Enbrel in January and therefore, retailers buy Enbrel in December itself. \u00a0The company calls the fall in sales of Enbrel as a seasonal head wind. \u00a0The results were taken negatively by the investors. It dropped more than 5% on intraday basis. \u00a0Amgen\u2019s stock has hardly gained 1% in last one year.<\/p>\n<p style=\"text-align: justify;\"><b>The lower revenues<\/b><\/p>\n<p style=\"text-align: justify;\">Amgen is the largest biotechnology company of world in terms of revenue. Amgen, Inc. (NASDAQ:AMGN)\u00a0reported the first quarter revenue at $4.52 billion which is a 6.6% increase on yearly basis. The analysts expected the revenues to come at $4.75 billion. Most of the analysts were expecting a better figure. Analyst projected the sale of Enbrel at $1.11 billion. However, it came at $988 million. It was a steep decline of 5%. The lower unit demands resulted in lower sales of Enbrel. Enbrel is the top selling drug of Amgen. It is one of the most sought medicines for Arthritis.<\/p>\n<p style=\"text-align: justify;\"><b>The yearly forecast<\/b><\/p>\n<p style=\"text-align: justify;\">Amgen main strength is Enbrel and the other anemia medicines led by Neulasta. The company is now taking necessary steps for the expansion of its portfolio of products. It is looking to follow the strategies of its peers to look beyond the obvious. Amgen is still firm on its yearly forecast of its revenues that is made earlier. It expects to post revenue of $19.2 billion to $19.6 billion in year 2014. It expects the EPS excluding one time items to come in the range of $7.90 to $8.20. Amgen, Inc. (NASDAQ:AMGN)\u00a0is optimistic to attain the targets of the year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 04\/24\/2014 (wallstreetpr) &#8211;\u00a0Amgen, Inc. (NASDAQ:AMGN) failed to meet the market expectations on its earnings in the first quarter 2014. The revenues didn\u2019t come [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":20241,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2831,1520],"stock_ticker":[],"class_list":["post-20239","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amgen-inc-nasdaqamgn","tag-nasdaqamgn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 04\/24\/2014 (wallstreetpr) &#8211;\u00a0Amgen, Inc. (NASDAQ:AMGN) failed to meet the market expectations on its earnings in the first quarter 2014. The revenues didn\u2019t come [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-24T15:17:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"224\" \/>\n\t<meta property=\"og:image:height\" content=\"54\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales\",\"datePublished\":\"2014-04-24T15:17:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239\"},\"wordCount\":307,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg\",\"keywords\":[\"Amgen Inc. (NASDAQ:AMGN)\",\"NASDAQ:AMGN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239\",\"name\":\"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg\",\"datePublished\":\"2014-04-24T15:17:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg\",\"width\":224,\"height\":54},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239","og_locale":"en_US","og_type":"article","og_title":"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales - Wall Street PR","og_description":"Boston, MA 04\/24\/2014 (wallstreetpr) &#8211;\u00a0Amgen, Inc. (NASDAQ:AMGN) failed to meet the market expectations on its earnings in the first quarter 2014. The revenues didn\u2019t come [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-04-24T15:17:29+00:00","og_image":[{"width":224,"height":54,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales","datePublished":"2014-04-24T15:17:29+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239"},"wordCount":307,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg","keywords":["Amgen Inc. (NASDAQ:AMGN)","NASDAQ:AMGN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239","url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239","name":"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg","datePublished":"2014-04-24T15:17:29+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/images-42.jpg","width":224,"height":54},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-decline-in-enbrel-sales-20239#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Amgen, Inc. (NASDAQ:AMGN): Decline In Enbrel Sales"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/20239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=20239"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/20239\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/20241"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=20239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=20239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=20239"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=20239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}